Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 2011. The report serves as a notification of transactions involving a Person Discharging Managerial Responsibility (PDMR) in the company's Ordinary Shares, specifically regarding the vesting of share options.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of executive compensation events rather than a financial performance report.
Material Changes
The material change disclosed is the completion of a three-year performance period for a Share Option Plan award granted in 2008. The performance period commenced on January 1, 2008, and concluded on December 31, 2010. Consequently, the entire original grant became exercisable.
Management Commentary and Unusual Items
The filing details a specific transaction for Mrs. V A Whyte, the Company Secretary. The share options were granted at an option price of £11.47. As of the notification date, 4,820 shares vested for Mrs. Whyte. The company and the individual were advised of this transaction on February 22, 2011, in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Checklist
- Verify the total number of shares vested for Mrs. V A Whyte (4,820 shares).
- Confirm the option price of the 2008 grant (£11.47).
- Check the vesting date and performance period end date (December 31, 2010).
- Note that this filing contains no financial performance data for the period.